Brian Cooley
« Rov qab mus rau Pab Pawg
Senior Vice President, Corporate Communications thiab Lymphatic Drug Development BU
- 30+ xyoo ntawm kev paub hauv biopharmaceutical thiab life science kev lag luam
- Mr. Cooley tuav ntau yam kev muag khoom, kev lag luam, thiab kev coj noj coj ua hauv kev lag luam ntawm hmoov zoo 500 tuam txhab thiab tau ua tiav kev nce nyiaj thiab pib siv zog rau cov tuam txhab kho mob thev naus laus zis
- Ua ntej koom nrog Sorrento, Mr. Cooley tau coj thoob ntiaj teb kev tshaj tawm cov khoom lag luam tshiab tshaj tawm kev siv zog nrog P&L lub luag haujlwm ntawm Eli Lilly thiab tuam txhab thiab Genentech hauv cov kab mob xws li Ntshav Qab Zib, Neurology, Immunology thiab Kab Mob Tsis tshua muaj.
- Tsis tas li ntawd, nws kuj tau coj cov BD tseem ceeb, hauv daim ntawv tso cai, thiab kev sib koom ua ke kev sib koom ua ke thoob ntiaj teb thiab hauv Teb Chaws Asmeskas Qhov no suav nrog ntau yam kev lag luam nthuav dav hauv Europe, Middle East thiab Africa, thiab daim ntawv cog lus $ 400MM kev sib koom tes rau hauv daim ntawv tso cai, tsim thiab ua lag luam. thawj GLP-1 agonist
- Tsis ntev los no, Mr. Cooley yog CBO rau Sofusa Business Unit ntawm Kimberly-Clark thiab coj kev muag khoom zoo thiab kev sib koom ua ke rau hauv Sorrento Therapeutics. Nws tseem ua tus thawj coj hauv Lymphatic Drug Delivery systems faib ntawm Sorrento.
- BS